July 1, 2025 2:00 pm EDT

Oss, Netherlands – July 1, 2025 – Organon has completed the acquisition of the MSD Biotech production site at De Geer in Oss. The formal handover ceremony took place today, attended by key local dignitaries and representatives from the management, supervisory board and works council of MSD and Organon.

Following the agreement that was announced last year, this acquisition will see 278 employees transfer to Organon, further expanding the company’s long-established presence in Oss. It includes all fertility activities and associated support roles. The drug substances for two of the company’s fertility products are manufactured at the Biotech Oss site. This investment will ensure Organon can continue to provide high-quality fertility products to patients worldwide.

Wenny Raaijmakers, Plant Manager of Organon in Oss, stated, “Our fertility franchise is a key area for Organon and the many patients who rely on our treatments.  Today marks an important step forward in supporting continued, quality manufacturing, and supply of these medicines for our patients as well as securing jobs in the region and strengthening our capability in this crucial area.  We are happy to welcome our new colleagues to Organon and we know that their knowledge and expertise will be invaluable as we expand our fertility business. We look forward to learning, sharing, and collaborating with our new team members to further support our important vision and mission.”

She continued “Organon is proud of its legacy in Oss and the expertise of its over 1,200 strong existing team in the area. The company is excited to expand its footprint and team in Oss. Organon looks forward to its existing site in Oss continuing to play an important role in its future as it builds and grows its position as a leading women’s healthcare company.”